137 related articles for article (PubMed ID: 19105704)
1. Gefitinib for the treatment of non-small-cell lung cancer.
Hida T; Ogawa S; Park JC; Park JY; Shimizu J; Horio Y; Yoshida K
Expert Rev Anticancer Ther; 2009 Jan; 9(1):17-35. PubMed ID: 19105704
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib for the treatment of non-small-cell lung cancer.
Campbell L; Blackhall F; Thatcher N
Expert Opin Pharmacother; 2010 Jun; 11(8):1343-57. PubMed ID: 20426712
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
Stinchcombe TE; Socinski MA
Oncologist; 2008 Sep; 13(9):933-44. PubMed ID: 18784157
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
Lee DH; Park K; Kim JH; Lee JS; Shin SW; Kang JH; Ahn MJ; Ahn JS; Suh C; Kim SW
Clin Cancer Res; 2010 Feb; 16(4):1307-14. PubMed ID: 20145166
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib in the treatment of advanced non-small-cell lung cancer.
Reck M
Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
[TBL] [Abstract][Full Text] [Related]
10. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
Park K; Goto K
Curr Med Res Opin; 2006 Mar; 22(3):561-73. PubMed ID: 16574039
[TBL] [Abstract][Full Text] [Related]
11. A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond.
Reck M
Expert Rev Anticancer Ther; 2010 Jun; 10(6):955-65. PubMed ID: 20553217
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
13. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
Morita S; Okamoto I; Kobayashi K; Yamazaki K; Asahina H; Inoue A; Hagiwara K; Sunaga N; Yanagitani N; Hida T; Yoshida K; Hirashima T; Yasumoto K; Sugio K; Mitsudomi T; Fukuoka M; Nukiwa T
Clin Cancer Res; 2009 Jul; 15(13):4493-8. PubMed ID: 19531624
[TBL] [Abstract][Full Text] [Related]
14. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
Maruyama R; Nishiwaki Y; Tamura T; Yamamoto N; Tsuboi M; Nakagawa K; Shinkai T; Negoro S; Imamura F; Eguchi K; Takeda K; Inoue A; Tomii K; Harada M; Masuda N; Jiang H; Itoh Y; Ichinose Y; Saijo N; Fukuoka M
J Clin Oncol; 2008 Sep; 26(26):4244-52. PubMed ID: 18779611
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib therapy for advanced non-small-cell lung cancer.
Liu CY; Seen S
Ann Pharmacother; 2003 Nov; 37(11):1644-53. PubMed ID: 14565788
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.
Ku GY; Haaland BA; de Lima Lopes G
Lung Cancer; 2011 Dec; 74(3):469-73. PubMed ID: 21565418
[TBL] [Abstract][Full Text] [Related]
17. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
18. Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
Reck M; Gatzemeier U
Lung Cancer; 2005 Oct; 50(1):107-14. PubMed ID: 15985306
[TBL] [Abstract][Full Text] [Related]
19. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
Cufer T; Vrdoljak E; Gaafar R; Erensoy I; Pemberton K;
Anticancer Drugs; 2006 Apr; 17(4):401-9. PubMed ID: 16549997
[TBL] [Abstract][Full Text] [Related]
20. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
